136 related articles for article (PubMed ID: 36376307)
21. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
Wallach AI; Schiebel M; Picone MA
Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
[TBL] [Abstract][Full Text] [Related]
22. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
23. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
Nielsen BU; Drabe CH; Barnkob MB; Johansen IS; Hansen AKK; Nilsson AC; Rasmussen LD
Front Immunol; 2022; 13():934476. PubMed ID: 35967433
[TBL] [Abstract][Full Text] [Related]
24. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Kamboj M
Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
[No Abstract] [Full Text] [Related]
25. Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
Oliva A; Cogliati Dezza F; Petrucci F; Romani FE; Morviducci M; Mirabelli FM; Cancelli F; Valeriani E; Marcelli G; Pugliese F; Turriziani O; Ricci P; Venditti M; Palange P; Mastroianni CM
Clin Exp Med; 2023 Oct; 23(6):2275-2285. PubMed ID: 36867292
[TBL] [Abstract][Full Text] [Related]
26. T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.
Atanackovic D; Kreitman RJ; Cohen J; Hardy NM; Omili D; Iraguha T; Burbelo PD; Gebru E; Fan X; Baddley J; Luetkens T; Dahiya S; Rapoport AP
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851312
[TBL] [Abstract][Full Text] [Related]
27. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.
Jiménez M; Roldán E; Fernández-Naval C; Villacampa G; Martinez-Gallo M; Medina-Gil D; Peralta-Garzón S; Pujadas G; Hernández C; Pagès C; Gironella M; Fox L; Orti G; Barba P; Pumarola T; Cabirta A; Catalá E; Valentín M; Marín-Niebla A; Orfao A; González M; Campins M; Ruiz-Camps I; Valcárcel D; Bosch F; Hernández M; Crespo M; Esperalba J; Abrisqueta P
Blood Adv; 2022 Feb; 6(3):774-784. PubMed ID: 34844263
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
[TBL] [Abstract][Full Text] [Related]
29. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
30. Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
Sidler D; Born A; Schietzel S; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Seyed Jafari SM; Radonjic-Hoesli S; Chan A; Hoepner R; Bacher U; Mani LY; Iype JM; Suter-Riniker F; Staehelin C; Nagler M; Hirzel C; Maurer B; Moor MB
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361691
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines.
Di Giacomo AM; Giacobini G; Anichini G; Gandolfo C; D'alonzo V; Calabrò L; Lofiego MF; Cusi MG; Maio M
Eur J Cancer; 2022 Aug; 171():143-149. PubMed ID: 35717822
[TBL] [Abstract][Full Text] [Related]
32. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
[TBL] [Abstract][Full Text] [Related]
33. Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
Poparn H; Srichumpuang C; Sosothikul D; Jantarabenjakul W; Lauhasurayotin S; Techavichit P; Chiangthong K; Poovorawan Y
Asian Pac J Cancer Prev; 2022 Jun; 23(6):2049-2055. PubMed ID: 35763647
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of antibody response after two doses of the Sinovac vaccine and the potential need for booster doses in cancer patients.
Ata S; Cil T; Duman BB; Unal N
J Med Virol; 2022 Jun; 94(6):2487-2492. PubMed ID: 35181932
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
[TBL] [Abstract][Full Text] [Related]
37. Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination.
Nakagama Y; Chi SG; Minami Y; Watanabe R; Yamagishi M; Atsuko U; Kido Y
J Infect Chemother; 2023 Jan; 29(1):112-114. PubMed ID: 36167304
[TBL] [Abstract][Full Text] [Related]
38. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
Saad Albichr I; De Greef J; Van Den Neste E; Poiré X; Havelange V; Vekemans MC; Bailly S; Yombi JC; Mzougui S; Scohy A; Kabamba-Mukadi B
Leuk Lymphoma; 2022 Mar; 63(3):743-746. PubMed ID: 34706604
[No Abstract] [Full Text] [Related]
39. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 vaccination in cancer patients: a narrative review.
Seneviratne SL; Yasawardene P; Wijerathne W; Somawardana B
J Int Med Res; 2022 Mar; 50(3):3000605221086155. PubMed ID: 35313761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
